Phase II STORM Trial: Selinexor + Dexamethasone Is Active in Patients With Heavily Pretreated Refractory MM

December 3-6, 2016; San Diego, California
First-in-class XPO1 inhibitor selinexor, in combination with low-dose dexamethasone, shows encouraging activity in heavily pretreated patients with MM refractory to multiple immunomodulatory agents, proteasome inhibitors, and anti-CD-38 monoclonal antibodies, according to the phase II STORM trial data.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.06 MB
Released: December 6, 2016


This activity is supported by educational grants from
Celgene Corporation
Merck & Co., Inc.
Seattle Genetics

Related Content

In this slideset from Clinical Care Options, experts provide insights on emerging CAR T-cell strategies for myeloma.

Noopur Raje, MD Released: December 3, 2020

CCO Conference Coverage of ASH 2020 with downloadable slides and experts’ commentaries of clinically relevant studies

Hanny Al-Samkari, MD John M. Burke, MD Jorge Cortes, MD Amy E. DeZern, MD, MHS Shaji Kumar, MD Sagar Lonial, MD person default Mark A. Schroeder, MD Jeff P. Sharman, MD Sujit Sheth, MD Srdan Verstovsek, MD, PhD Eunice S. Wang, MD Released: December 2, 2020

From Clinical Care Options (CCO), expert commentary on key new developments in CAR T-cell therapy and a preview of CAR T-cell data at ASH 2020

Michael Wang, MD Released: December 1, 2020

CCO commentary from Shaji Kumar, MD, on key issues in the management of multiple myeloma

Shaji Kumar, MD Released: November 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.